Table 4.
Relationship of treatment parameters with occurrence of adverse events.
| No AE (n = 13) | Any AE (n = 46) | p | No Grade ≥ 3 AE (n = 47) | Grade ≥ 3 AE (n = 12) | p | |
|---|---|---|---|---|---|---|
| Diagnosis | ||||||
| Bladder | 3 (42.9%) | 4 (57.1%) | 0.0659 | 7 (100%) | 0 (0%) | 0.4952 |
| Melanoma | 3 (16.7%) | 15 (83.3%) | 14 (77.8%) | 4 (22.2%) | ||
| NSCLC | 0 (0%) | 5 (100%) | 5 (100%) | 0 (0%) | ||
| Pancreas | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) | ||
| RCC | 5 (18.5%) | 22 (81.5%) | 19 (70.4%) | 8 (29.6%) | ||
| SCC HN | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) | ||
| No. of ICI | ||||||
| Single | 11 (27.5%) | 29 (72.5%) | 0.1893 | 35 (87.5%) | 5 (12.5%) | 0.0417 |
| >1 ICI | 2 (10.5%) | 17 (89.5%) | 12 (63.2%) | 7 (36.8%) | ||
| ICI status | ||||||
| Simultaneous | 1 (7.1%) | 13 (92.9%) | 0.1591 | 8 (57.1%) | 6 (42.9%) | 0.0260 |
| Othera | 12 (26.7%) | 33 (73.3%) | 39 (86.7%) | 6 (13.3%) | ||
| Treatment order | ||||||
| ICI → RT (ICI first) | 3 (27.3%) | 8 (72.7%) | 0.9153 | 11 (100%) | 0 (0%) | 0.1765 |
| RT + ICI (simultaneous) | 6 (20.0%) | 24 (80.0%) | 23 (76.7%) | 7 (23.3%) | ||
| RT → ICI (RT first) | 4 (22.2%) | 14 (77.8%) | 13 (72.2%) | 5 (27.8%) | ||
| Single fractionsb | ||||||
| 1 fraction | 1 (16.7%) | 5 (83.3%) | 1.0000 | 5 (83.3%) | 1 (16.7%) | 1.0000 |
| >1 fraction | 8 (25.8%) | 23 (74.2%) | 26 (83.9%) | 5 (16.1%) | ||
| 1-3 fractionsc | ||||||
| 1–3 fractions | 3 (16.7%) | 15 (83.3%) | 1.0000 | 13 (72.2%) | 5 (27.8%) | 0.2320 |
| >3 fractions | 4 (21.1%) | 15 (78.9%) | 17 (89.5%) | 2 (10.5%) | ||
| Other concurrent RTd | ||||||
| Yes | 6 (28.6%) | 15 (71.4%) | 0.5131 | 16 (76.2%) | 5 (23.8%) | 0.7386 |
| No | 7 (18.4%) | 31 (81.6%) | 31 (81.6%) | 7 (18.4%) | ||
| Head and Neck RT | ||||||
| No | 9 (25.0%) | 27 (75.0%) | 0.4916 | 29 (80.6%) | 7 (19.4%) | 0.8309 |
| Yes | 4 (17.4%) | 19 (82.6%) | 18 (78.3%) | 5 (21.7%) | ||
| Bone RT | ||||||
| No | 8 (19.0%) | 34 (81.0%) | 0.3844 | 32 (76.2%) | 10 (23.8%) | 0.2979 |
| Yes | 5 (29.4%) | 12 (70.6%) | 15 (88.2%) | 2 (11.8%) | ||
| Lung and Chest RT | ||||||
| No | 8 (25.8%) | 23 (74.2%) | 0.4620 | 23 (74.2%) | 8 (25.8%) | 0.2723 |
| Yes | 5 (17.9%) | 23 (82.1%) | 24 (85.7%) | 4 (14.3%) | ||
| Below Diaphragm RT | ||||||
| No | 6 (18.2%) | 27 (81.8%) | 0.4213 | 27 (81.8%) | 6 (18.2%) | 0.6428 |
| Yes | 7 (26.9%) | 19 (73.1%) | 20 (76.9%) | 6 (23.1%) | ||
| Median BED (Gy), total (IQR) | 127.3 (83.5-160.0) | 131.8 (77.5-206.5) | 0.5043 | 127.3 (75.4-201.0) | 146.0 (97.3-185.4) | 0.5157 |
| Median infusions (IQR) | 4 (2-8) | 8 (4-15) | 0.1020 | 8 (4-15) | 4 (3.5-7.5) | 0.0632 |
| Median ICI duration (mos), months (IQR) | 2.7 (1.0-4.5) | 3.8 (2.1-8.3) | 0.1798 | 3.8 (2.1-8.3) | 3.2 (1.7-4.1) | 0.2247 |
Abbreviations: AE, adverse events; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; SCC HN, head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitor; RT, radiotherapy; BED, biologically equivalent dose; IQR, inter-quartile range.
a
Other included those who received single or >1 sequential but no concurrent ICIs.
b
Patients who only received 1 fraction versus patients who only received more than 1 fraction to all treated sites.
c
Patients who only received 1–3 fractions versus patients who only received more than 3 fractions to all treated sites.
d
This included conventional RT or brain SRS.